Residency · Residency · Radiation Oncology

Early-Stage Non-Small Cell Lung Cancer: SBRT for Medically Inoperable Patients

Overview

Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), is a technique that delivers high doses of precisely targeted radiation over a small number of treatment sessions, typically between one and five fractions. SBRT has become the standard of care for patients with medically inoperable stage I non-small cell lung cancer (NSCLC), specifically those with tumors classified as T1-T2a N0 M0. This approach achieves impressive local control rates ranging from 90% to 97% at three years. In many retrospective comparisons, the outcomes of SBRT approach those seen with surgical lobectomy, the traditional treatment for operable patients. The successful delivery of SBRT requires rigorous management of tumor motion, advanced image guidance, and precise small-field dosimetry. Despite its established role in inoperable patients, whether SBRT should be offered to operable patients remains a highly debated topic in thoracic oncology.

Clinical Trial Evidence

The RTOG 0236 trial, conducted by Timmerman et al. in 2010, was a phase II single-arm study evaluating SBRT in medically inoperable stage I NSCLC patients with tumors up to 5 cm (T1-T2). Patients received a dose of 54 Gy delivered in three fractions of 18 Gy each, without correction for tissue heterogeneity. This regimen resulted in a 3-year primary tumor control rate of 97.6% and a 3-year local control rate, including the involved lobe, of 90.6%. Overall survival (OS) at three years was 55.8%, limited primarily by comorbidities rather than cancer-related deaths. This study established SBRT as a highly effective local therapy for this patient population.

RTOG 0618, another phase II study by Timmerman et al. in 2018, assessed the same SBRT dose regimen (54 Gy in 3 fractions) but in operable stage I NSCLC patients. The 4-year primary tumor control rate was 96%, and the 4-year OS was 56%, which was comparable to outcomes seen in inoperable cohorts despite the operable status of these patients. This trial demonstrated the feasibility and efficacy of SBRT in operable patients, although definitive phase III data are still lacking.

The Japanese JCOG 0403 study was a phase II trial that included both operable and inoperable stage I NSCLC patients treated with 48 Gy in 4 fractions. The operable cohort achieved a 3-year OS of 76.5% and local control of 86%, while the inoperable cohort had a 3-year OS of 59.9%.

The CHISEL randomized controlled trial compared SBRT to conventional radiotherapy in inoperable stage I NSCLC patients. SBRT was superior to conventional fractionation for local control, with a hazard ratio of 0.32 (p=0.002), confirming SBRT as the standard treatment over conventional radiotherapy in this setting.

Several trials have compared SBRT to surgery in operable patients. The STARS and ROSEL trials were prematurely closed phase III studies whose pooled analysis suggested a possible overall survival advantage for SBRT, with a 3-year OS of 95% versus 79% for surgery. However, the small sample size of only 58 patients limits the strength of this conclusion. Other randomized trials such as VALOR and STABLEMATES are ongoing, as are studies like SABR-BRIDGE and POSTILV. To date, no definitive phase III data establish SBRT as equivalent to lobectomy for operable patients.

Dose-Fractionation Schemes

For peripheral lung tumors, several dose-fractionation regimens are commonly used. The RTOG 0236 protocol prescribes 54 Gy in 3 fractions, which corresponds to a biologically effective dose (BED10) of 151.2 Gy. Other regimens include 50 Gy in 5 fractions (BED10 = 100 Gy), 48 Gy in 4 fractions (BED10 = 105.6 Gy), which is commonly used in Japan, and a single-fraction regimen of 34 Gy (BED10 = 149.6 Gy) used selectively. The general principle is that a BED10 of at least 100 Gy is associated with optimal local control rates exceeding 90%.

Central tumors, defined as those within 2 cm of the proximal bronchial tree, require more cautious fractionation due to increased risk of toxicity. Timmerman described a "no-fly zone" for 3-fraction regimens (such as 54 Gy in 3 fractions) in central lesions because of fatal complications like hemorrhage and bronchial stricture. The RTOG 0813 trial, a phase I/II dose escalation study, evaluated doses ranging from 50 to 60 Gy in 5 fractions for central tumors. The recommended dose from this trial is 50 Gy in 5 fractions, which demonstrated safety and efficacy, with 12 Gy per fraction showing acceptable toxicity. The ongoing NRG-LU002 phase III trial is comparing SBRT to conventional radiotherapy for central tumors. Alternative risk-adapted fractionations include 60 Gy in 8 fractions. Ultra-central tumors, which abut critical structures such as the proximal bronchial tree, trachea, or great vessels, may require even more conservative fractionation schemes, such as 50 Gy in 5 fractions, 60 Gy in 8 fractions, or 70 Gy in 10 fractions.

Tumors adjacent to the chest wall carry a risk of rib fracture, occurring in up to 30% of cases, and chest wall pain. Although there is no strong consensus to alter fractionation specifically for chest wall-adjacent tumors, some institutions prefer 5-fraction regimens over 3-fraction schedules to mitigate this risk. The volume of chest wall receiving 30 Gy (V30) correlates with the risk of rib fracture.

Treatment Planning and Delivery

Simulation for SBRT involves 4D-CT imaging to assess respiratory motion. The internal target volume (ITV) is defined to encompass the tumor's motion throughout the entire respiratory cycle. If tumor motion exceeds 1 cm, techniques such as abdominal compression, breath hold, or respiratory gating may be employed. Intravenous contrast can be used to aid mediastinal delineation, although it is not mandatory.

Target volumes are defined starting with the gross tumor volume (GTV), which is the visible tumor on CT, often correlated with PET-CT findings. No elective nodal coverage is included. The ITV represents the GTV at all respiratory phases, delineated either by maximum intensity projection or manual contouring on each phase. The planning target volume (PTV) is created by adding a margin of 3 to 5 mm to the ITV, depending on institutional protocols and image-guided radiotherapy (IGRT) capabilities. Unlike conventional radiotherapy, no clinical target volume (CTV) expansion for microscopic disease is added in SBRT because the high dose is considered sufficient.

Dose is prescribed to the periphery of the PTV, commonly at the 80% isodose line for most linear accelerator-based SBRT treatments. The dose distribution within the target is heterogeneous, with the GTV typically receiving 120-150% of the prescription dose. The conformality index (R100), defined as the ratio of the prescription isodose volume to the PTV volume, ideally should be less than or equal to 1.2. The gradient index, which is the ratio of the 50% isodose volume to the prescription isodose volume, should ideally be less than 5 to ensure rapid dose falloff outside the target.

Organ-at-risk constraints for a 3-fraction SBRT scheme include a maximum spinal cord dose of less than 18 Gy (6 Gy per fraction), esophagus maximum dose under 27 Gy (9 Gy per fraction), brachial plexus maximum dose below 24 Gy (8 Gy per fraction), heart or pericardium maximum dose under 30 Gy (10 Gy per fraction), and great vessels maximum dose below 39 Gy (13 Gy per fraction). For the chest wall, the volume receiving 30 Gy (V30) should be kept under 30 cc to minimize rib fracture risk. The proximal bronchial tree should receive a maximum dose under 30 Gy in 3-fraction regimens for peripheral tumors.

Image guidance is mandatory for SBRT, with daily cone-beam CT (CBCT) used to verify tumor position. Four-dimensional CBCT is preferred to confirm tumor location relative to the ITV. Implanted fiducial markers, such as gold seeds, can be used for real-time tracking with systems like CyberKnife or Varian Calypso. Surface-guided radiotherapy is employed for breath-hold techniques to further improve accuracy.

Post-SBRT Assessment

Following SBRT, imaging follow-up typically involves chest CT scans every 3 to 6 months for the first two years, then every 6 to 12 months thereafter. Radiation-induced fibrosis is a common and expected benign parenchymal change seen on CT, manifesting as consolidation, ground-glass opacities, or scarring. These changes can follow several patterns, including modified conventional, mass-like, or scar-like fibrosis. PET-CT can assist in distinguishing fibrosis from tumor recurrence, although standardized uptake values (SUV) may remain elevated for 12 to 24 months post-SBRT, necessitating serial PET assessments. When imaging findings are equivocal but there is a high suspicion of recurrence, biopsy may be warranted.

High-risk features indicating local unsuccessful SBRT (HILUS) include enlarging opacities with bulging margins, loss of air bronchograms, and loss of linear margins on imaging, which suggest tumor recurrence. Most recurrences occur within 2 to 3 years after treatment, with late recurrences being uncommon.

<image>A four-panel figure showing representative SBRT dose distributions for lung tumors in different anatomic locations. Panel A: peripheral right upper lobe tumor treated with 54 Gy/3 fractions, showing tight conformality with rapid dose falloff. Panel B: central tumor adjacent to the right main bronchus treated with 50 Gy/5 fractions, with dose-volume histogram inset showing bronchial tree dose constraint compliance. Panel C: chest wall-abutting tumor with rib dose highlighted. Panel D: ultra-central tumor abutting the carina treated with 60 Gy/8 fractions. Each panel shows the 100%, 50%, and 20% isodose lines.</image>

<image>A timeline graphic showing the evolution of lung SBRT clinical trials from RTOG 0236 (2004-2006 accrual) through RTOG 0618, RTOG 0813, CHISEL, STARS/ROSEL, and currently enrolling VALOR/STABLEMATES trials. Key outcomes (local control, OS, toxicity) are annotated for completed trials. The transition from "inoperable only" to "potentially operable" patient populations is highlighted.</image>

<image>A CT imaging follow-up series showing post-SBRT changes at 3, 6, 12, and 24 months after treatment of a peripheral right lower lobe tumor. The progression from acute consolidation to ground-glass opacity to mature scar-like fibrosis is demonstrated. An adjacent panel shows a recurrence case with enlarging mass-like opacity and bulging margins at 18 months, contrasted with the benign fibrosis pattern.</image>

Key Clinical Pearls

SBRT is the undisputed standard of care for medically inoperable stage I NSCLC, achieving local control rates of 90% to 97% that rival those reported in surgical series. However, overall survival is often limited by patients’ comorbidities rather than cancer progression. A biologically effective dose (BED10) of at least 100 Gy is the threshold associated with optimal local control, so dose compromise for peripheral tumors should be avoided unless there is a compelling reason. Central and ultra-central tumors require modified fractionation schedules, typically involving 5 to 8 fractions, to reduce the risk of fatal complications such as hemorrhage, bronchial stricture, and esophageal fistula. The concept of a 3-fraction "no-fly zone" for central tumors remains clinically relevant. Post-SBRT fibrosis seen on CT is expected and should not be mistaken for recurrence; serial imaging combined with PET-CT is the primary method to distinguish benign changes from local failure. Finally, the question of whether SBRT is equivalent to surgery in operable patients remains unanswered by definitive phase III data, and the limited STARS/ROSEL pooled analysis should not be overinterpreted due to its very small sample size.

References

• Timmerman R et al. "Stereotactic body radiation therapy for inoperable early stage lung cancer." JAMA. 2010;303(11):1070-1076.
• Timmerman RD et al. "Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer." JAMA Oncol. 2018;4(9):1287-1288.
• Ball D et al. "Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial." Lancet Oncol. 2019;20(4):494-503.
• Bezjak A et al. "Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 trial." J Clin Oncol. 2019;37(15):1316-1325.
• Chang JY et al. "Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials." Lancet Oncol. 2015;16(6):630-637.

Read this lecture as Markdown